Radiation Safety for Oncological Patients before and after Nuclear Medicine Procedures and Radiation Safety of Nursing Staff
2025-09-19 13:30 - 14:30 (Europe/Vienna)
This webinar will emphasize the critical importance of radiation protection in safeguarding both the occupational health of care providers and the well-being of patients undergoing radionuclide therapy.

It will underscore the necessity of adhering to established guidelines and protocols when handling radioactive materials to ensure safety and treatment efficacy.

Furthermore, the session will explore the role of interprofessional collaboration and continuing education among health care providers in enhancing radiation safety practices. It will also present evidence-based strategies to mitigate patients’ symptoms associated with the adverse effects of radionuclide treatment.

Register now!Enrol in the live webinar now for free! Register now

Learning Objectives

To identify the primary steps for introducing newly hired health care staff to radionuclide therapy protocols and recognize the importance of continuous education in maintaining adherence to institutional safety and procedural standards.

To evaluate various educational methods and strategies used to train health care providers—including nurses, caregivers, seasonal workers, and clinical assistants—in the principles, procedures, and safety protocols of radionuclide therapy.

To demonstrate effective patient education techniques and symptom management strategies for individuals undergoing radionuclide therapy, with attention to minimizing adverse effects and enhancing patient comprehension.

To compare different radiation safety protocols and clinical guidelines associated with Lutathera and radioiodine therapies, with respect to implications for both patients and health care providers.

Target Audience

All health care providers involved in the care of oncological patients undergoing radionuclide treatment in clinical practice

Faculty

Lace MatarloSpeaker

Matthias Hellberg-NaegeleModerator

Sigrid Leide SvegbornSpeaker

Explainable AI
2025-10-24 13:30 - 14:30
The webinar will provide first the fundamentals and basics of explainable artificial intelligence, including the tools for interpretability of machine and deep learning models, as well as the explainability principles. Second, it will provide how these concepts are translated and applied to the development of AI-based models for nuclear medicine applications.

Register nowEnrol in the live webinar now for free! Register now

Learning Objectives

Attendees will be able to understand what are the concepts and methods that define explainable AI, including interpretability tools and algorithms, as well as explainability concepts to translate these to the end-users.

Attendees will be able to discover how these concepts can be used to facilitate the development, adoption and trust for end-users of AI-based models in nuclear medicine applications.

Target Audience

Nuclear medicine physicians, scientists and technologists interested in the application of artificial intelligence in nuclear medicine imaging applications.

Faculty

Neo Christopher ChungSpeaker

Clemens SpielvogelSpeaker

Mathieu HattModerator

Event Overview

Bringing Alpha Therapies into Clinical Practice
2025-10-30 08:00 - 2027-11-30 17:00 | Online
UEMS EACCME has granted the accreditation of 3 CME credits for this event.

This online course offers a comprehensive introduction to alpha therapy in nuclear medicine, with a focus on the fundamental principles and clinical applications of Alpha-Therapy in the fields of Radiopharmaceutical Sciences, Oncology and Dosimetry. Alpha Therapy is a cutting-edge cancer treatment using alpha radiation. It represents a form of targeted radionuclide therapy that uses alpha-emitting radioisotopes to deliver lethal doses of radiation directly to cancer cells while sparing healthy tissues. It is highly efficient and lately increasingly explored for scientific purposes in the oncologic domain . With this course we aim at bringing Alpha Therapies into clinical practice through various, relevant presentations. A panel of experts and EANM members will update you on the type of alpha-emitting radioisotopes available, describing all important steps required for production and radiopharmaceutical development. The advantages, but also the challenges related to the use of Alpha therapy will amply be discussed and supported by clinical examples. You will be initiated in the existing and ongoing therapeutic trials, with the best yet to come. Dosimetry will play a pivotal role in this course, underlying its role in clinical practice. Finally, The Alphamet project will be presented, allowing you to get updated with the latest insights from Theranostics.

RPH

Targeted Alpha Therapy (TAT) represents a cutting-edge advancement in cancer treatment, harnessing the potent, cell-killing power of alpha particles to precisely destroy malignant cells while minimizing damage to surrounding healthy tissue. This part of the course course explores the transformative potential of TAT, highlighting its exceptional potency, unique ability to overcome radio-resistance, and its role in modern theranostics. You’ll gain insight into the selection of optimal alpha-emitting radionuclides, the biological advantages of short-range high-energy emissions, and the complex challenges involved in the development, production, and clinical translation of these innovative therapies. Join us to deepen your knowledge and be part of the future of targeted radiopharmaceuticals in oncology.

Oncology

In this part of the course, participants will explore the main advantages of alpha-emitting radionuclides in oncology, while also gaining an understanding of the clinical challenges associated with their use. You will become familiar with the key clinical aspects of Alpha-Therapy, supported by real-world perspectives and case insights. The course also highlights current and upcoming therapeutic trials, providing valuable knowledge on the future direction of this rapidly evolving field.

Dosimetry

Participants will begin by exploring the basic concepts of dosimetry with alpha emitters, highlighting key differences from beta emitter dosimetry. The course then delves into the clinical relevance of alpha dosimetry, demonstrating how accurate dose assessments can inform and optimize the management of patients undergoing treatment with alpha radiotherapeutics. In addition, the course presents the Alphamet project, a major European initiative that addresses the specific metrological challenges associated with targeted alpha therapies. By examining the goals and contributions of Alphamet, learners will gain insight into how this research supports the safe and effective integration of alpha therapy into routine clinical practice.

Save yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!

Learning Objectives

To gain an overview of the main advantages of Alpha-radionuclides

To learn about the challenges of alpha emitters, complex production; transport issues, waste management and handling

To get insights on radiobiology: radiotoxicity & effectiveness

To have a comprehensive review of research candidates

To provide an overview of the main advantages when using Alpha-Therapy in clinical practice

To learn about the clinical challenges when using Alpha-Therapy

To get insights into current and future trials focusing on Alpha-Therapy

To learn the most basic aspects about dosimetry of alpha emitters showing the main differences with dosimetry of beta emitters

To learn how dosimetry results could be used in the management of patients treated with radiopharmaceuticals that include alpha emitters

To learn on the Alphamet project, which addresses the unique and unmet metrological challenges of targeted alpha therapies, contributing to their safe and optimised implementation into routine clinical practice

Target Audience

Nuclear medicine physicians, radiologists, medical oncologists, urologists, radiation oncologists, medical physicists, biologists, researchers

Radiochemists, radiopharmacists, physicists, medical physicists, biologists

ProgrammeClick to see the full event programme. View the Programme

Faculty

Dana NiculaeSpeaker

Emma AnaheimSpeaker

Janke KleyhansSpeaker

Marianna TosatoSpeaker

Wolfgang FendlerSpeaker

Mathias ZacherlSpeaker

Pablo Mínguez GabiñaSpeaker

Mike SathekgeSpeaker

Daniela Oprea-LagerSpeaker

Ana Denis-BacelarSpeaker

Joe O’SullivanSpeaker

myEANM accountLog into your myEANM account or create a new one.

ESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations

Enroll yourselfFind your desired course under ‘Online Courses’

Enjoy!Once enrolled, you get full access to the course contents on the ESMIT eLearning platform

Event Overview

Nuclear Medicine-related Highlights from ESMO 2025
2025-11-07 13:30 - 14:30
This ESMO 2025 webinar will cover a range of topics, including the latest advancements treatment options, imaging modalities and performant tracers related to solid and liquid tumors. The focus of this Live event will be the recent advances in solid & liquid tumor treatment, clinical trials and emerging therapies, biomarkers in solid tumors and multidisciplinary approaches. The importance of collaboration among medical oncologists, radiologists, nuclear medicine physicians, pathologists and surgeons will be underlined, based on clinical examples. Challenges and opportunities in immunotherapy for solid tumors will also be addressed, with special attention for personalized treatment plans in specific cancers, like lung cancer, breast cancer, colorectal and prostate cancer.

Please note that the webinar will be recorded, and the recording will be available a few days after the session is over. You can find the recording on the ESMIT E-learning platform, under the webinar title. A handout of the presentation materials will also be available on the platform.

Register nowEnrol in the live webinar now for free! Register now

Learning Objectives

Attendees will get insight into recent advances in solid/ liquid tumor treatment

Attendees will be familiarized with the latest developments when diagnosing, staging and treating different types of solid and liquid tumors.

Target Audience

Fellows and Medical Specialists in Nuclear Medicine, Radiology, Medical Oncology, Urology, Surgery, Pathology and Radiation Oncology

Faculty

David KerstingModerator

Karolien GoffinSpeaker

Matthias EiberSpeaker

Event Overview

Paediatric Thyroid Cancer
2025-11-14 13:30 - 14:30
This webinar aims to underly the most relevant differences with the adults DCT regarding epidemiology, genetics, pathology, immunoistopathology, diagnostic tools and treatment, especially for RAI theranostic procedure. Additionally, the webinar will also go over the main GL recommendations, as well as present and discuss two emblematic or tricky cases.

Register nowEnrol in the live webinar now for free! Register now

Learning Objectives

The aim of this course is to sensitise the attendees about the correct way to recognise, diagnose and treat DTC in children.

Target Audience

Physicians, residents with special interest on endocrinlogy and endo-oncology, nuclear medicine specialists, nurses and technicians of nuclear medicine units.

Suggested Readings

Francis GL, Waguespack SG, Bauer AJ, Angelos P, Benvenga S, Cerutti JM, Dinauer CA, Hamilton J, Hay ID, Luster M, Parisi MT, Rachmiel M, Thompson GB, Yamashita S; American Thyroid Association Guidelines Task Force. Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015 Jul;25(7):716-59. doi: 10.1089/thy.2014.0460. PMID: 25900731; PMCID: PMC4854274.

Lebbink CA, Links TP, Czarniecka A, Dias RP, Elisei R, Izatt L, Krude H, Lorenz K, Luster M, Newbold K, Piccardo A, Sobrinho-Simões M, Takano T, Paul van Trotsenburg AS, Verburg FA, van Santen HM. 2022 European Thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma. Eur Thyroid J. 2022 Nov 29;11(6):e220146. doi: 10.1530/ETJ-22-0146. PMID: 36228315; PMCID: PMC9716393.

Czarniecka A, Woźniak G, Kropińska A, Jarząb B, Handkiewicz-Junak D. Surgical approach to differentiated thyroid cancers (DTC) in children [Specyfika leczenia chirurgicznego zróżnicowanych raków tarczycy (ZRT) u dzieci]. Endokrynol Pol. 2019;70(4):357-366. doi: 10.5603/EP.a2019.0033. PMID: 31489960.

Faculty

Desiree DeandreisSpeaker

Catia OliantiModerator

Livia LamartinaSpeaker

Event Overview

Focus on FDG PET/CT in Inflammatory and Infectious Diseases
2025-11-20 09:00 - 2025-11-21 12:30 | Future Health Lab, Alfred-Adler-Straße 1, Vienna, 1100, Austria
Inflammation comes from the Latin word inflammare, to ignite or to set on fire – we want to ignite your interest in imaging inflammation and infection.

Inflammatory and infectious diseases can be clinically challenging. Many are systemic with highly variable clinical presentations and sometimes vague and non-specific symptoms and findings. Association with implanted material like artificial heart valves, joint or vascular prostheses may hamper imaging or give rise to non-specific findings.

Although the imaging strategy may still be considered unclarified in some settings, [18F]FDG-PET/CT is now established as a key modality in the diagnostic workup of several inflammatory and infectious diseases. The course aims to provide the participants with an overview of the evidence and practical use of [18F]FDG-PET/CT in suspected inflammation and infection and covers the most well-established indications.

Led by European experts, the sessions mix short overview lectures with interactive sessions to allow participants to engage in discussions and exchange experiences on daily practices with each other and the faculty.

Register nowThe course is fully booked. Please contact us at esmit@eanm.org if you would like to be added to the waiting list!

Learning Objectives

To provide general insights into the use of [18F]FDG PET/CT in suspected or manifest inflammation and infection, e.g. patient preparation and protocols

To provide insights into how and when to use [18F]FDG PET/CT in suspected or manifest specific inflammatory diseases, e.g. vasculitis, polymyalgia rheumatica, other reumatologic diseases, and sarcoidosis

To provide insights into how and when to use [18F]FDG PET/CT in suspected or manifest specific infectious diseases, e.g. fever and inflammation of unknown origin, blood stream infections, osteomyelitis and spondylodiscitis, cardiac and vascular infections

To provide some insights into novel developments with this domain, e.g. FAPI, bacteria-specific tracers, and long axial field of view scanners

To facilitate an open discussion on pro and cons of [18F]FDG PET/CT in suspected or manifest inflammation and infections

Target Audience

Nuclear medicine specialists with basic experience in reading [18F]FDG-PET/CT in inflammatory and infectious diseases.

ProgrammeView the Programme

Faculty

Soren HessSpeakerOdense, Denmark

Olivier GheysensSpeakerBrussels, Belgium

Ayah NawwarSpeakerBristol, UK

Giorgio TregliaSpeakerLugano, Switzerland

Registration Details

Registration FeeMode of PaymentCancellation Policy

Course Fee € 950.-

Registration Fee includes:

Electronic Course Book, including all Slides

Coffee & Lunch Breaks

Registration Fee does NOT include:

Travel to the Venue

Accommodation

Registration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline, the registration needs to be cancelled. Payment can be settled by Credit Card Cheques will not be accepted

Cancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course, we will refund you the fee less a € 100,- administration charge. After this date, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels, airlines or other means of transportation.

Japanese vs. European View on Targeted Radionuclide Therapy
2025-12-01 10:00 - 11:00
This event is a collaboration between ESMIT and JSNM. The aim of the webinar is to compare the approach to targeted radionuclide therapy (TRT) in Japan and in Europe. The webinar will focus on the differences in the TRT environment in Japan vs. Europe, including regulatory science and radiation protection regulation, and more.

Register nowEnrol in the live webinar now for free! Register now

Target Audience

Nuclear Medicine Physicians

Faculty

Tatsuya HigashiSpeaker

Wolfgang FendlerSpeaker

Conrad-Amadeus VoltinModerator

Event Overview

Nuclear Medicine in Breast Cancer Based on FOCUS Meeting 6
2025-12-04 08:00 - 2025-12-05 17:00 | Future Health Lab, Alfred-Adler-Straße 1, Vienna, 1100, Austria
Breast cancer is the most relevant cancer in women worldwide. It is the second most frequently diagnosed cancer (after lung cancer) and the first leading cause of cancer-related death in women, being the fourth globally regardless of gender. By 2040, breast cancer is predicted to increase to over 3 million new cases and 1 million deaths per year.

Staging patients with breast cancer is challenging due to its heterogeneous nature and presentation. Imaging is of utmost importance in all clinical settings, particularly, in staging, assessing therapy response, and detecting recurrence. Despite the well-stablished usefulness of radiologic modalities, Nuclear Medicine has demonstrated an important role to play in breast cancer, which has been increasingly supported by strong scientific evidence. Considering the patient’s long survival, the benefits of assessing active tumour in an accurate way, gain major importance in these patient’s care.

The recent equipment and radiopharmaceutical developments have opened the path to improve tumour characterization through several imaging possibilities. Currently, the challenge is to use the correct combination of equipment and tracer at the right time. Furthermore, homogenize imaging and clinical procedures is becoming even more important.

During this course, the highlights from the consensus reached during the multidisciplinary EANM Focus Meeting 6 about Nuclear Medicine diagnostics and therapeutics possibilities will be comprehensively presented and discussed in a close way between the faculty and attendees.

Register nowRegistration is now open, save yourself a seat! Register now

Learning Objectives

To understand breast cancer as a heterogeneous disease, its characteristics and evolution;

To define the role of nuclear medicine techniques in different clinical settings (initial staging, assessing therapy response, and detecting recurrence);

To know the potential usefulness of PET tracers beyond FDG in each breast cancer subtype and use of the evolving PET technology & equipment;

To discuss future diagnostic and treatment approaches with radiopharmaceuticals.

Target Audience

Nuclear Medicine physicians, Radiologists, Medical Oncologists, Radiation Oncologists, Medical students, Residents, Nurses, Nuclear Medicine technologists and Radiographers.

ProgrammeView the Programme

Faculty

Sofia VazSpeakerLisbon, Portugal

Thiemo van NijnattenSpeakerMaastricht, Netherlands

Philipp BackhausSpeakerMünster, Germany

Registration Details

Registration FeeMode of PaymentCancellation Policy

Course Fee € 950.-

Registration Fee includes:

Electronic Course Book, including all Slides

Coffee & Lunch Breaks

Registration Fee does NOT include:

Travel to the Venue

Accommodation

Registration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline, the registration needs to be cancelled. Payment can be settled by Credit Card Cheques will not be accepted

Cancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course, we will refund you the fee less a € 100,- administration charge. After this date, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels, airlines or other means of transportation.

To AI or not to AI in Neurology: That is the Question
2025-12-12 13:30 - 14:30
This webinar will explore state-of-the-art AI approaches for advancing neuroimaging, with a particular focus on quantitative PET. It will cover the entire imaging pipeline, from preprocessing, acquisition, and tomographic reconstruction to quantification, segmentation, denoising, and resolution enhancement, demonstrating how modern AI can enable more reproducible and robust brain PET biomarkers. Through two expert presentations and practical case examples, the webinar will showcase how AI-driven methodologies are reshaping neuroimaging research and supporting more accurate diagnosis and disease monitoring.

Register nowEnrol in the live webinar now for free! Register now

Learning Objectives

Learn the principles behind AI-based quantitative PET methods

Understand how AI can enhance each stage of the neuroimaging pipeline, from preprocessing and reconstruction to segmentation, denoising, and resolution recovery.

Critically assess when AI meaningfully improves neuroimaging workflows

Recognize emerging opportunities and challenges in integrating AI tools into brain PET

Target Audience

Nuclear physicians, medical physicists, imaging scientists and radiologists working in PET neuroimaging

Faculty

Pablo Aguilar FernándezModerator

Dimitris VisvikisSpeaker

Charalampos TsoumpasSpeaker

Event Overview

Fundamentals of Research in Imaging and Theranostics – Part 1: Research Design
2026-12-31 00:00 - 23:59 | Online
UEMS EACCME has granted the accreditation of 4 CME credits for this event.

This online course is part of a long line of research methodology which is aimed at providing interested participants with information about the preclinical development and clinical translation, as well as the design, conductance and reporting of clinical research trials, with a specific emphasis on radiopharmaceuticals for both diagnostic and therapeutic applications.

These first two modules will represent part one of the course.

Module 1 will focus on the entire path from preclinical development to clinical translation of an imaging compound, including the preclinical studies needed for the selection of a new candidate for clinical translation, an overview of EU legislation on radiopharmaceuticals for diagnosis and therapy, and the assessment of quality data and non-clinical data (pharmacology, dosimetry and toxicology) for the IMP dossier.

Module 2 will be focused on the design of a proper trial. It will cover: the definition of objectives, aims, endpoints, population, statistical methods and examples of trial design schemes, as well as dosimetry as far as healthy organs and in case of therapy tumour-absorbed dose. It will have a special focus on phase 0, phase 1-2 trial, early clinical phase 0-1-2 and investigator-driven clinical trial.

Save yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!

Learning Objectives:

Learn about:

Preclinical development and clinical translation of radiopharmaceuticals

The legislation on radiopharmaceuticals with a specific focus on the European scenario

Requirements of IMPD for radiopharmaceuticals for imaging agents and theranostic/therapeutic molecules Interpretation of preclinical data to properly design and plan the clinical trial

Phase 0, phase 1 and phase 2 clinical trials with radiopharmaceuticals design

Phase 0, phase 1 and phase 2 clinical trials with radiopharmaceuticals conductance

GMP, GLP and GCP principles

Importance of radioprotection and dosimetric estimates in early phase clinical trials

Target Audience:

Researchers, scientists, nurses, pharmacologists, radiopharmacists, residents and specialists in Nuclear Medicine/Oncology/Radiology who want to understand how clinical trials with radiopharmaceuticals in the early phase are unique and how the corresponding documents and trial design should be appropriately planned.

ProgrammeClick to see the full event programme. View the Programme

Faculty

Paola Anna ErbaUniversità degli Studi di Milano-Bicocca, Italy

Sona BalogovaComenius University, Bratislava, Slovakia

Elisabeth von GuggenbergMedical University Innsbruck, Austria

Martina SolliniVita-Salute San Raffaele University, Milan, Italy

Luigi AlojUniversity of Cambridge, United Kingdom

Meltem OcakIstanbul University, Turkey

Peter LavermanRadboud Universiteit Nijmegen, The Netherlands

Jane SosabowskiQueen Mary, University of London, United Kingdom

Petra KolencUniversity Medical Centre Ljubljana, Slovenia

Clemens DecristoforoMedical University Innsbruck, Austria

Piotr GarnuszekPOLATOM, Warsaw, Poland

Renata MikolajczakPOLATOM, Warsaw, Poland

Theodosia MainaNCSR Demokritos, Athens, Greece

Mark KonijnenbergErasmus MC, Rotterdam, The Netherlands

Registration Details

Registration Fee

Course Fee Free

Event Overview
